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ABSTRACT  
Hollow glycopolymer microcapsules were fabricated by hydrogen-bonded layer-by-layer (LbL) 
assembly and their interactions with a set of antigen presenting cells (APCs), including dendritic 
cells (DCs), macrophages (MACs) and myeloid derived suppressor cells (MDSCs) were 
investigated. The glycopolymers were obtained by cascade post-polymerization modifications of 
poly(oligo(2-ethyl-2-oxazoline methacrylate)-stat-glycidyl methacrylate) involving anionic ring-
opening of the glycidyl groups with propargylamine and the subsequent attachment of mannose 
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azide by copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC). Multilayer assembly of the 
hydrogen-bonding pair (glycopolymer/poly(methacrylic acid) (PMAA)) onto planar and 
particulate supports (SiO2 particles, d = 1.16 μm) yielded stable glycopolymer films upon cross-
linking by CuAAC. Hollow monodisperse capsules were obtained after removal of the silica 
(SiO2) particle templates, as demonstrated by fluorescence and scanning electron microscopy. 
Cellular uptake studies using flow cytometry revealed the preferential uptake of the capsules by 
DCs when compared to MACs or MDSCs. Mannosylated capsules showed a cytokine 
independent cis-upregulation of CD80 specifically on DCs and a trans-downregulation of PDL-1 
on MDSCs. Thus, the glycopolymer capsules may have the potential as vaccine carriers, as they 
are able to upregulate costimulatory molecules for immune cell stimulation on DCs and at the 





Polysaccharides are natural occurring polymers that play important roles in our immune system, 
e.g. in cellular recognition processes and pathogen infections. Sugar binding proteins, so called 
lectins are often overexpressed on the surface of antigen presenting cells (APC) and can interact 
with sugar ligands, (for example like those expressed on bacterial cell walls) and trigger or 
regulate immune responses.1,2 In recent years this specific interaction has stimulated the interest 
in glycomimetic materials with improved therapeutic efficiencies.3,4 Synthetic glycopolymers 
have been demonstrated to be superior oligosaccharide mimics because they enable the 
incorporation of multiple saccharides along a polymer backbone and thus amplification of 
carbohydrate-lectin/cell interactions,5,6 also known as the cluster glycoside effect.7 To date, 
diverse polymerization techniques have been exploited for the synthesis of defined 
glycopolymers,8-12 including but not limited to, reversible deactivation radical polymerizations 
(RDRPs), ring-opening metathesis polymerization (ROMP), and ring-opening polymerizations 
(ROPs). The self-assembly of glycopolymers or the surface modification of particles with sugar 
units give rise to even more sophisticated materials, namely glycoparticles, which not only show 
carbohydrate-specific interactions but additionally exploit the beneficial physiochemical 
properties of particulate systems.13-15 To date, a wide range of glycosylated carriers has been 
fabricated, such as micelles, polymersomes, and metallic, magnetic, and self-assembled 
nanoparticles.  
Preferential uptake of particles by specific types of antigen presenting cells (APCs) such as 
dendritic cells (DCs), macrophages (MACs) or myeloid derived suppressor cells (MDSCs), can 
lead to different immune responses and eventually different therapeutic outcomes. Uptake by 
DCs is usually a key step to induce adaptive immune responses, and has been a major focus of 
synthetic vaccine development for infectious diseases and cancer.16,17 By contrast, uptake by 
MACs or MDSCs can lead to either activation or conversely suppression of immune responses, 
and is being explored to develop therapeutics against autoimmune and allergic diseases.18 The 
state of activation of the APCs and the type of surface molecules that they upregulate after 
interacting with particles, will also influence their ability to activate or suppress immune 
responses. In this context, MACs and MDSCs that express high levels of the programmed death 
ligand 1 (PDL1) have high capacity to turn off immunity by interacting with programmed death 
1 (PD1) molecules present on diverse immune cells such as T cells and NK cells.19 By contrast, 
 4 
activated mature DCs that express high levels of molecules that allow them to effectively interact 
with T cells, such as CD80, are classically strong activators of immunity.20 Herein, we explore 
the balance of preferential uptake of glycomimetic layer-by-layer (LbL) microparticles by DCs 
compared with MACs and MDSCs, as well as the potential change in key regulatory molecules 
CD80 and PDL1 on these different APC subsets.  
Poly(2-oxazoline)s (POx) are an emerging polymer class,21 which have attracted significant 
attention in the biomaterials area22,23 since they combine excellent biocompatibility24-27 and 
protein repellence properties28 along with the ease of synthesizing highly functional materials.29-
32 Recently, we reported the LbL assembly of POx-based systems for the fabrication of low-
fouling, redox- and enzyme-degradable and targeted hollow polymer capsules.33-35 The LbL 
approach36,37 has attracted increasing interest for the engineering of particulate delivery 
systems,38,39 as it allows tailoring of the physical and chemical properties of the carriers. 
Previously, particular focus was placed on the design of brush-like POx by RDRPs as they allow 
for the incorporation of further functional groups that are beneficial for covalent or reversible 
cross-linking and labelling or modification with targeting units of the capsules post-assembly. 
Copper-catalyzed alkyne-azide cycloaddition (CuAAc)33,35 and dynamic thiol-disulfide exchange 
reactions34 were employed depending on the desired application, for example for the 
modification of the capsule surface with a phage-display derived single-chain antibody (scFv) for 
the specific targeting of activated platelets.35 Other interesting targeting ligands that are readily 
available are mono- and disaccharides. Over the last decade, a range of glycopoly(2-oxazoline)s 
has been reported using glycosylated 2-oxazoline monomers40 or post-polymerization reactions 
such as thiol-ene chemistry.41-43 An elegant approach for the synthesis of glycosylated brush-like 
POx was reported by Weber et al. using telechelic POx macromonomers with α-sugar and ω-
methacrylate end groups.44  
In this work, we demonstrate the fabrication of LbL assembled glycopoly(2-oxazoline)-based 
capsules. To the best of our knowledge, the formation of hollow multilayered capsules by 
hydrogen-bonded LbL of glycopolymers has not yet been reported. The glycopolymer was 
obtained by a combination of living/controlled polymerization techniques and highly efficient 
post-polymerization modifications. Alkyne functionalities introduced during this process were 
then exploited for the modification with mannose moieties, labeling and multilayer crosslinking. 
The mannosylated films and capsules showed specific interactions with the lectin concanavalin 
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A (ConA). All capsules types tested were clearly preferentially taken up by DCs when compared 
to MACs or MDSCs. Moreover, the functional characteristics of the microparticles are further 
investigated in their capacity to downregulate PDL1 on multiple APC types, including 
professional suppressor APCs such as MDSCs. Only mannosylated capsules were capable of 
selectively upregulating CD80 specifically on DCs (but not MDSCs or MACs). The mechanism 
by which these molecules are controlled was further explored by the use of fluorescently labeled 
microparticles, providing evidence for the existence of two mechanisms: cytokine independent 
cis-activation for CD80 up-regulation specifically on DCs, and broad trans-downregulation of 
PDL1 across multiple cell types (balanced against particle uptake induced up-regulation). 
Together these results point to useful novel dual properties for mannosylated particles, making 
them suitable vaccine carriers, by virtue of being taken up by DCs and downregulating broadly 
immune inhibitory receptors on suppressor APCs such as MDSCs, while selectively being able 
to upregulate costimulatory molecules for immune cell stimulation on DCs.   
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RESULTS AND DISCUSSION 
Copolymer synthesis. Mannosylated brush-like PEtOx-based copolymers (PEtOxMAMan) were 
prepared by a combination of cationic ring-opening polymerization (CROP), atom transfer 
radical polymerization (ATRP), efficient ring-opening reaction of glycidyl side chains and 
copper(I)-catalyzed azide-alkyne cycloaddition (CuAAC, Scheme 1). The PEtOx 
macromonomer, namely oligo(2-ethyl-2-oxazoline methacrylate) (OEtOxMA), was synthesized 
by CROP of 2-ethyl-2-oxazoline (EtOx) initiated with methyl tosylate and terminated with 
methacrylic acid (Scheme S1).45 The copolymerization of OEtOxMA with glycidyl methacrylate 
(GMA) by ATRP yielded highly functional copolymers (PEtOxMAGMA), which can be 
efficiently modified through ring-opening reaction with nucleophiles. In this way, brush-like 
PEtOx with pendant alkyne moieties were prepared (PEtOxMAAlk), which were further 
functionalized with mannose azide in a CuAAC reaction to yield PEtOxMAMan.   
Scheme 1. Synthesis of mannosylated poly(oligo(2-ethyl-2-oxazoline methacrylate)) brush 
copolymer (PEtOxMAMan). (A) Base-catalyzed ring-opening reaction using propargylamine 
(PEtOxMAAlk). (B) Introduction of mannose moieties by CuAAC (PEtOxMAMan). 
 
1H NMR spectroscopy was used to determine the degree of polymerization (DP) and 
functionalization (DF). EtOx was polymerized with a monomer-to-initiator ratio of 6:1 to full 
conversion of the monomer before the living chain ends were terminated with methacrylic acid 
to give the OEtOx6MA macromonomer. ATRP of OEtOxMA and GMA provided functional 
PEtOx-containing copolymers with 17 mol% glycidyl groups, as determined by the ratio of the 
integrals of the GMA peaks (2.5 ̶ 2.9 ppm) and the CH2 peak of the PEtOx side chain (2.1 ̶ 2.5 
ppm). The GMA groups were quantitatively converted into alkyne groups by treatment with 
propargylamine (Figure 1A, top), as can be seen by the disappearance of the respective 1H NMR 
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peaks (2.5 ̶ 2.9 ppm, 4.2 ppm). The modification of PEtOxMAAlk with mannose azide via 
CuAAC resulted in the formation of triazole groups, which was confirmed via a 1H NMR signal 
at 8.1 ppm (Figure S1). The degree of functionalization was determined by comparing the 
integral ratio of the triazole and the CH2 PEtOx signal, which revealed an overall mannose 
content of 6 mol%. Thus, PEtOxMAMan still contains unreacted alkyne groups, which can be 
used for further post-polymerization reactions, such as cross-linking reactions and labeling. Size 
exclusion chromatography (SEC) measurements revealed the synthesis of defined copolymers 
with dispersity (Ð) values < 1.4. A shift to higher molar masses was observed by both post-
polymerization modifications, the ring-opening reaction with propargyl amine and CuAAC with 
mannose azide (Figure 1B). 
 
Figure 1. (A) 1H NMR spectra (400 MHz, CDCl3) of poly[oligo(2-ethyl-2-oxazoline 
methacrylate)-stat-glycidyl methacrylate] (PEtOxMAGMA) synthesized by ATRP (bottom), 
which was modified with propargylamine (PEtOxMAAlk) in a base-catalyzed ring-opening 






Multilayer Assembly on Planar and Particle Supports. Quartz crystal microbalance (QCM) 
and flow cytometry were used to monitor the assembly of PEtOxMAAlk/PMA and 
PEtOxMAMan/PMA multilayer films via hydrogen bonding, respectively. Polymer solutions were 
prepared at 1 mg mL-1 (50 mM NaOAc, pH 4) and five PEtOxMAx/PMA bilayers were 
iteratively deposited. For QCM studies, an additional PEI (1 mg mL-1, 0.5 M NaCl) layer was 
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initially deposited onto the gold surface of the QCM crystal prior to the layer buildup. PMA was 
allowed to adsorb for 15 min before washing the film in NaOAc buffer. Subsequently, 
PEtOxMAx was adsorbed for 20 min followed by the next washing step. This procedure was 
repeated four more times. The formation of hydrogen-bonded PEtOxMAx/PMA multilayer films 
was confirmed by a frequency decrease with increasing number of polymer layers (Figure S2A). 
The deposition of the PEtOxMAMan/PMA bilayer system showed only a slightly higher 
frequency change compared to the PEtOxMAMan/PMA bilayer system, suggesting a similar 
hydrogen-bonding interaction of both systems.  
To examine the multilayer film formation on particle supports, PEtOxMAx and AF488-
cadaverine labeled PMA (PMA488) were deposited alternatively onto monodisperse SiO2 
particles (1.16 µm in diameter) at pH 4. The particles were incubated in the respective polymer 
solutions for 15 min before washing them via three centrifugation/re-dispersion cycles, as 
detailed in the Experimental Section. After the deposition of each bilayer the fluorescence 
intensity of the core/shell particles was measured by flow cytometry. For both bilayer systems a 
regular and linear layer buildup was observed (Figure S2B) similarly to the QCM studies.   
 
Scheme 2. Preparation of PEtOxMAAlk and PEtOxMAMan capsules via hydrogen-bonded LbL 
assembly of PEtOxMAAlk (non-mannosylated) or PEtOxMAMan (mannosylated) and PMA. 
For the fabrication of hollow mannosylated and non-mannosylated polymer capsules, five 
PEtOxMAMan/PMA and PEtOxMAAlk/PMA bilayers, respectively, were deposited onto 
monodisperse SiO2 particles (1.16 µm) and cross-linked with a non-degradable bisazide cross-
linker similar to a procedure reported for other CuAAC "click" capsules previously (Scheme 
2).46 Remaining alkyne groups in the multilayer films were further modified with azide-
functionalized Alexa Fluor 488 (AF488Az) to provide a suitable fluorescent tag for subsequent 
cell studies. After removal of the particle template by hydrogen fluoride (HF) treatment and the 
 9 
sacrificial PMA layers by washing the capsules into PBS (pH 7.4), stable hollow capsules were 
obtained. Analysis of the capsules using fluorescence microscopy showed spherical capsules 
with diameters consistent with the used template for both the non-mannosylated (Figure 2A) and 
mannosylated (Figure 2B) capsules. In addition, capsule morphology and size were analyzed 
using SEM (Figure 2C/D), which showed spherical structures with folds and creases typical for 
stabilized LbL polymer capsules. 
 
Figure 2. Fluorescence (A, B; scale bar = 5 µm) and scanning electron (C, D; scale bar = 2 µm) 
microscopy images of PEtOxMAAlk (A, C) and PEtOxMAMan (B, D) capsules. Multilayer 
assembly was performed on sacrificial SiO2 particles (1.16 μm diameter) at pH 4 (NaOAc, 50 
mM). The core-shell particles were treated with HF to remove the core and washed into PBS to 
remove sacrificial PMA. The capsules were labeled with azide-functionalized Alexa Fluor 488 
(AF488Az). 
 
Concanavalin A (ConA) binding studies. Lectins, which are carbohydrate-binding proteins 
play an important role in biological processes including cell proliferation and death. 
Glycopolymers or glycopolymer assemblies are capable of multivalent binding to lectins, a 
process known as the "cluster-glycoside effect".7 Concanavalin A (ConA) is a lectin, which 
specifically binds to mannosyl and glucosyl residues. ConA possesses four binding sites, which 
enable the binding of up to four sugar groups resulting in protein aggregation when a multivalent 
carbohydrate or glycopolymer is employed.  
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Figure 3. Concanavalin A (ConA) binding studies on, (A) PEtOxMAAlk and PEtOxMAMan 
planar films, as monitored by QCM, t1: deposition of ConA (0.2 mg mL-1, HBS buffer), t2: wash 
with HBS buffer. PEtOxMAAlk and PEtOxMAMan surfaces were obtained by sequential 
deposition of PEI (1 mg mL-1), PMAAlk (1 mg mL
-1) and PEtOxMAx/PMA (1 mg mL
-1); (B) 
PEtOxMAMan capsules assessed by fluorescence microscopy. Scale bar = 5 µm. 
 
QCM measurements were performed to provide evidence of the binding of the glycopolymer 
films to ConA. To this end, the gold surfaces of the QCM chips were coated with PEI and 
PMAAlk. The latter was used to deposit PEtOxMAAlk and PEtOxMAMan via hydrogen bonding 
interaction, respectively, and stabilize the film at physiological pH using CuAAC chemistry. 
Upon exposure of the PEtOxMAMan film to ConA, a significant decrease in frequency was 
observed. In contrast, the PEtOxAlk film showed only marginal frequency changes (Figure 3a). 
This is indicative of a specific interaction between the mannose containing film and the 
carbohydrate-binding protein. Non-mannosylated and mannosylated capsules were also 
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investigated for their potential to interact with ConA. Both capsule types were incubated with 
AF647 labeled ConA and examined using fluorescence microscopy. PEtOxMAAlk capsules 
remained individually dispersed (as shown in Figure 2A), whereas PEtOxMAMan aggregated 
significantly (Figure 3b). The overlay of the AF488 and AF647 channels further proved the 
ConA-driven aggregation (Figure S3). 
Effects of capsules on viability and composition of bone marrow cultures. Subsequently, the 
interaction of the capsules with a range of cells derived from bone marrow was investigated. For 
potential use in vaccine delivery the capsules need to possess negligible toxicity. This was 
investigated by the assessment of the effect of capsules on the viability of bone marrow derived 
dendritic cells (BMDCs) designed to induce functionally relevant APCs such as DCs, MACs and 
MDSCs. Overall, cell viability in these cultures was not negatively affected by any of the 
capsules, independent of the capsule type and concentration (30 vs. 300 capsules per cell, 
referred to ‘30’ or ‘300’ in the figures) tested. Soluble PEtOxMAMan at the corresponding doses 
to those used on the capsules was also found to be not toxic. Lipopolysaccharide (LPS), used in 
subsequent studies as a positive control stimulatory agent was also confirmed to be non-toxic at 
the standard dose. Similar results were observed after 1 h (data not shown) or 18 h of incubation 
(Figure 4A), with no differences in cell viability across all treatment groups compared to the no 
treatment group. Additionally, there were no changes in the proportional frequency of DCs 
(CD11c+Gr1-), MACs (CD11c-Gr1-) or MDSCs (CD11c-Gr1+) over 1 h (not shown) or 18 hrs 
of co-culture with the different formulations (Figure 4B). 
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Figure 4. Cell viability of BMDC cultures (A) and antigen presenting cell (APC) phenotypes (B) 
after 18 h co-culture with different capsule types. The effect of capsules on cells were tested on 
BMDCs cultures. BMDCs were co-cultured with PEtOxMAAlk and PEtOxMAMan capsules at 30 
or 300 capsules/cell or control agent (LPS) for 1 or 18 h, at which time point cells were 
harvested and stained with various antibodies that define the phenotypes of the cells, e.g., 
MDSCs (CD11c-Gr1+); DCs (CD11c+Gr1-), MACs (CD11c-Gr1-), and analyzed by flow 
cytometry. Cell viability (A) were determined by live/dead staining; and the effect of capsules on 
the APCs in major APC phenotypes were determined by the percentage of MHCII expression in 
each type of immune cells. N=4 for each treatment conditions. 
 
Capsule uptake by different APC subsets. All capsule types, regardless of surface 
modification by mannose, showed preferential uptake by stimulatory rather than inhibitory APC 
subsets. Hence, as shown in Figure 5, capsules were preferentially internalized by conventional 
DCs (CD11c+Gr1-), MACs (CD11c-Gr1-,) and then by MDSCs (CD11c-Gr1+) after 18 h co-
culture. The effect was titratable, with more cells taking up capsules at higher capsule doses.    
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Figure 5. Capsule uptake by different APC populations. Capsules (PEtOxMAAlk and 
PEtOxMAMan) uptake was tested on BMDC cultures at 30 or 300 capsules/cell, and determined 
by the percentage of capsule positive cells in each APC population after 18 h of co-culturing 
particles and BMDCs as detailed in the Experimental Section. N=4 for each treatment 
conditions. 
 
DC and MAC activation and maturation induced by the capsules. Stimulation via pathogen 
recognition receptors (PRRs), such as toll like receptor 4 (TLR4) for LPS or the mannose 
receptor, activates and matures APC and enables them to perform important functions, such as 
naïve T cell priming by ‘licensed’ DCs. The molecule CD80 is a vital functional marker for this 
process. Expression of CD80 was analyzed on all three key types of APCs, DCs, MACs and 
MDSCs (Figure 6A) after 18 h co-culture with the different types of capsules or controls, 
including LPS as a positive control. As expected, CD80 expression was significantly enhanced in 
LPS stimulated cells on both DCs and MACs, and to a lesser degree on MDSCs (Figure 6A). 
PEtOxMAAlk capsules did not induce CD80 expression on any cell type tested. In contrast, 
PEtOxMAMan capsules showed large and significant increases in CD80 expression on DCs 
compared to the other groups, including the treatment group with soluble PEtOxMAMan at an 
equivalent concentration to that present on the capsules. To further determine whether CD80 
upregulation was due to a direct (cis) interaction between the capsules and DCs or to an indirect 
(trans) effect mediated by soluble cytokines, we analyzed the cells which had either internalized 
or not internalized the capsules in the same culture. Figure 6B shows clearly that only DCs that 
had taken up capsules (Cap+ cells) also up-regulate CD80 expression.  
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PDL-1 is an important negative modulator of immune function, and is associated with a 
tolerogenic DC phenotype.47 Expression of PDL-1 was determined on the three types of APC 
cell types studied after treatment with the control LPS, soluble PEtOxMAMan, PEtOxMAAlk and 
PEtOxMAMan capsules. LPS treatment significantly increased PDL-1 expression (Figure 6C) in 
all cell types studied (DCs, MDSCs and MACs). By contrast, high doses of capsule particles 
decreased PDL-1 expression on DCs across the cultures, independent of the type of capsule. An 
analysis of cells that had taken up capsules compared to those that did not, revealed PDL-1 
downregulation on DCs in the absence of particle uptake, suggesting significant trans effects for 
PDL-1 downregulation (Figure 6D). By contrast, overall PDL-1 expression, found also 




Figure 6. Activation/maturation of immune cells (A, B) and effect of the immune-regulatory 
functions (C, D) by capsule particles. (A) Overall activation molecule CD80 expression; (B) 
differential CD80 expression in cells taken up capsules (Cap+) and no capsule cells (Cap-); (C) 
overall immune-regulatory molecule PDL-1 expression; and (D) differential PDL-1 expression in 
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cells taken up capsules (Cap+) and no capsule cells (Cap-). BMDC were cultured with 
PEtOxMAAlk and PEtOxMAMan capsules at 30 or 300 capsules/cell or control agent (LPS) for 18 
h, at which time point cells were harvested and stained antibodies specifically for activation 
molecules such as CD80 (A, B) and PDL-1 (C, D). Data were presented as mean fluorescence 
intensity (MFI) of CD80 expression. N=4 for each treatment conditions. 
 
CONCLUSIONS 
Mannosylated hollow poly(2-oxazoline)-based capsules were successfully prepared by 
hydrogen-bonding LbL assembly of a mannosylated brush poly(oligo(2-ethyl-2-
oxazoline)methacrylate). The copolymer was synthesized in a three-step cascade employing a 
combination of cationic ring-opening polymerization, controlled radical polymerization and 
efficient post-polymerization modifications. The mannosylated multilayer films were prepared 
on both planar and particle supports and showed interactions with a mannose-specific lectin in 
contrast to non-mannosylated films. A preferential uptake of the capsules in DCs as compared to 
MACs and MDSCs was observed, independent of the mannosylation. However, only 
mannosylated capsules triggered a significant upregulation of costimulatory molecules for 
immune cell stimulation on DCs, without upregulation of inhibitory receptors such as PDL-1. 
This finding contrasts conventional ‘danger signal’ activation via TLR4 by LPS, which 
massively upregulates PDL-1, particularly on the immune-suppressive MDSC subset. The results 
obtained demonstrate the potential of these mannosylated capsules as future vaccine carriers, 
highlighting some potential beneficial properties of particulate glycopolymer systems, while also 
noting the challenges associated with the translation of lectin-glycopolymer interactions to in 






Materials and Instrumentation 
Silica particles (1.16 μm) were purchased from MicroParticles GmbH (Germany) as a 5 wt% 
suspension and were used as received. Poly(methacrylic acid, sodium salt) (PMA, 30 wt%), Mw 
15 kDa, was purchased from Polysciences (USA). 2-Ethyl-2-oxazoline, methyl tosylate, and 
triethylamine were purchased from Sigma-Aldrich, distilled to dryness and stored under argon. 
Acetonitrile, anisole, glycidyl methacrylate (GMA), ethyl α-bromoisobutyrate (EBIB), 
N,N,N′,N′′,N′′-pentamethyldiethylenetriamine (PMDETA), copper(I) bromide (CuBr),  
dimethylsulfoxide (DMSO), propargylamine, phosphate buffered saline (PBS) tablets, and 
buffering salts were purchased from Sigma-Aldrich and used as received. HEPES buffered saline 
(HBS; 10 mM HEPES, 150 mM NaCl, pH 7.4) containing 1 mM Ca2+, Mg2+ and Mn2+ was 
prepared by mixing the appropriate salts. Alexa Fluor 488 azide (AF488Az) was obtained from 
Life Technologies, Inc. High-purity water with a resistivity greater than 18 MΩ cm was obtained 
from an in-line Millipore RiOs/Origin water purification system (Milli-Q water). Mannose azide 
was prepared according to a literature procedure.  
Nuclear magnetic resonance (1H NMR) spectra were recorded in deuterated solvents (CDCl3, 
DMSO-d6) using a 400 MHz Varian INOVA system at 25 °C. SEC analyses of polymer samples 
were performed using a Shimadzu modular system comprising a DGU-12A degasser, an SIL-
20AD automatic injector, a 5.0 μm bead-size guard column (50 × 7.8 mm) followed by three KF-
805L columns (300 × 8 mm, bead size: 10 μm, pore size maximum: 5000 Å), a SPD-20A 
ultraviolet detector, and an RID-10A differential refractive-index detector. The temperature of 
columns was maintained at 40 °C using a CTO-20A oven. The eluent was N, N-
dimethylacetamide (DMAc, HPLC grade, with 0.03% w/v LiBr) and the flow rate was kept at 1 
mL min-1 using a LC-20AD pump. A molecular weight calibration curve was produced using 
commercial narrow molecular weight distribution polystyrene standards with molecular weights 
ranging from 500 to 2 × 106 g mol-1. Polymer solutions at approx. 3 mg mL-1 were prepared and 
filtered through 0.45 μm filters prior to injection.  
Fluorescence microscopy measurements were performed with an inverted Olympus IX71 
microscope equipped with a DIC slider (U-DICT, Olympus) with a 60× objective lens (Olympus 
UPLFL20/0.5 N.A., W.D. 1.6) and used to visualize the capsules. A CCD camera (Cool SNAP 
fx, Photometrics, Tucson, AZ) was mounted on the left hand port of the microscope. 
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Fluorescence images were illuminated with an Hg arc lamp using a UF1032 filter cube. Scanning 
electron microscopy (SEM) images were obtained using a FEI Quanta 200 field emission 
scanning electron microscope operated at an accelerating voltage of 10 kV. 
 
Polymer synthesis and post-modifications 
Oligo(2-ethyl-2-oxazoline methacrylate) (OEtOxMA): The OEtOxMA macromonomer (Scheme 
S1) was synthesized as follows: a solution of methyl tosylate (I; 1.86 g; 10 mmol) and 2-ethyl-2-
oxazoline (EtOx; 4 g; 40 mmol) was prepared in acetonitrile (3.8 g; 92.6 mmol). The total 
monomer concentration was adjusted to 4 M with a [EtOx]:[I] ratio of 4:1. The sealed vial was 
heated to 85 °C in an oil bath for 60 min. After cooling, methacrylic acid (1.29 g; 15 mmol) and 
triethylamine (2 g; 20 mmol) were added to the polymerization mixture and stirring was 
continued overnight at 50 °C. Subsequently, the polymer was purified by washing with sodium 
bicarbonate and brine. The combined organic phases were dried over magnesium sulfate, filtered 
and the solvent was removed under reduced pressure. OEtOxMA was obtained after drying the 
polymer for 2 days. 1H NMR analysis demonstrated the quantitative conversion of the monomer 
and quantitative functionalization with methacrylic acid. SEC (DMAc, PS standard): Mn = 1 020 
g mol-1, Ð = 1.13. 
Poly(oligo(2-ethyl-2-oxazoline methacrylate)-stat-glycidyl methacrylate) (PEtOxMAGMA): 
PEtOxGMA was prepared by atom transfer radical polymerization (ATRP). OEtOxMA (1 g; 2 
mmol) and PMDETA (19.9 mg; 0.11 mmol) were dissolved in anisole (3 mL) and degassed for 
30 min. In parallel, GMA (187.4 mg; 1.32 mmol) and EBIB (6.5 mg; 0.033 mmol) were 
dissolved in anisole (1 mL), CuBr (15.5 mg; 0.11 mmol) was added and the suspension was 
degassed for 30 min. The total monomer concentration was adjusted to 0.6 M with a 
[OEtOxMA]:[GMA]:[EBIB] ratio of 60:40:1. The OEtOxMA solution was added to the CuBr 
suspension and then reacted at 60 °C for 22 h. After cooling to room temperature, the polymer 
was precipitated in ice-cold diethyl ether, re-dissolved in dichloromethane and passed through a 
neutral alumina column. Subsequently, the polymer was dialyzed against Milli-Q for 3 days 
(MWCO = 3.5 kDa) and recovered by freeze-drying. 1H NMR revealed 47% and 53% 
conversion for OEtOxMA and GMA, respectively. 1H NMR (400 MHz, CDCl3, δ): 4.5 – 4.2 
(COO-CH2 GMA), 4.2 – 3.3 (N-CH2 OEtOxMA), 3.3 – 3.1 (CHO GMA), 3.1 – 2.9 (CH3N 
OEtOxMA), 2.9 – 2.5 (CH2O GMA), 2.5 – 2.1 (CH2 OEtOxMA), 2.0 – 1.4 (CH2 methacrylate 
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backbone), 1.3 – 0.9 (CH3 OEtOxMA), 0.9 – 0.6 (CH3 methacrylate backbone); SEC (DMAc, PS 
standard): Mn = 17 500 g mol
-1, Ð = 1.37. 
Post-polymerization modification of PEtOxMAGMA with propargylamine (PEtOxMAAlk). 
PEtOxGMA (150 mg; 0.0085 mmol), propargylamine (76 mg; 1.37 mmol) and triethylamine (138 
mg; 1.37 mmol) were dissolved in dry DMSO (2 mL) and the solution was stirred at 50 °C 
overnight. Subsequently, the solvent was removed under reduced pressure. The polymer was re-
dissolved in methanol and dialyzed against methanol for 1 day and subsequently against Milli-Q 
for 2 days (MWCO = 3.5 kDa). PEtOxMAAlk was recovered by freeze-drying. 
1H NMR (400 
MHz, CDCl3, δ): 4.3 – 3.2 (N-CH2 OEtOxMA, COO-CH2 GMA), 3.1 – 2.9 (CH3N OEtOxMA), 
2.5 – 2.1 (CH2 OEtOxMA), 2.0 – 1.4 (CH2 methacrylate backbone), 1.3 – 0.9 (CH3 OEtOxMA), 
0.9 – 0.6 (CH3 methacrylate backbone); SEC (DMAc, PS standard): Mn = 30 200 g mol-1, Ð = 
1.28. 
Post-polymerization modification of PEtOxMAAlk with mannose azide (PEtOxMAMan). PEtOxAlk 
(20 mg; 0.0011 mmol), mannose azide (2.6 mg; 0.011 mmol) and PMDETA (3.65 mg; 0.02 
mmol) were dissolved in DMF (0.5 mL) and the solution was deoxygenated for 30 min before 
the addition of CuBr (3 mg; 0.02 mol). The reaction mixture was subsequently stirred at room 
temperature for 19 h. To remove unreacted compounds and CuBr/PMDETA the polymer was 
dialyzed against Milli-Q (MWCO = 3.5 kDa) for 3 days and passed through a NAP-25 column. 
PEtOxMAMan was recovered by freeze-drying. 
1H NMR (400 MHz, DMSO-d6, δ): 8.25 – 7.9 
(triazole), 6.0 – 4.5 (mannose), 4.25 – 3.0 (N-CH2 OEtOxMA, COO-CH2 GMA), 3.0 – 2.8 (CH3N 
OEtOxMA), 2.4 – 2.0 (CH2 OEtOxMA), 2.0 – 1.25 (CH2 methacrylate backbone), 1.25 – 0.75 
(CH3 OEtOxMA), 0.75 – 0.5 (CH3 methacrylate backbone); SEC (THF, PS standard): Mn = 42 
900 g mol-1, Ð = 1.4. 
 
Film and capsule preparation 
Multilayer Assembly on Planar Supports: Gold-coated 5 MHz AT-cut crystals (Q-Sense AB, 
Västra, Frölunda, Sweden) were cleaned with piranha solution (7:3 v/v sulfuric acid/hydrogen 
peroxide) for 20 min followed by extensive rinsing in water, drying with nitrogen, and exposure 
(20 min) to UV (Bioforce NanoScience, USA). Caution! Piranha solution is very corrosive. 
Extreme care should be taken when handling piranha solution, and only small quantities should 
be prepared. QCM measurements were conducted using a QCM-D E4 device with four flow 
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cells (Q-Sense AB, Västra, Frölunda, Sweden). All frequency values quoted are for the third 
overtone. The other overtones measured (fifth and seventh overtones) followed the same trend. 
According to the Sauerbrey equation, a frequency change of 1 Hz corresponds to a film mass of 
17.7 ng cm-2 for the 5 MHz QCM crystals used. The temperature was kept constant at 23 °C for 
the entire deposition process. After initially depositing a layer of PEI (1 g L-1 in 0.5 M NaCl, 10 
min; washed with Milli-Q and subsequently with 20 mM NaOAc pH 4), PMA (1 g L-1 in 20 mM 
NaOAc, pH 4) and PEtOxMAx (1 g L
-1 in 20 mM NaOAc, pH 4) were sequentially adsorbed to 
the films until a total number of 9 layers was obtained. After each adsorption step, the films were 
washed with 0.5 mL NaOAc (20 mM, pH 4).  
Multilayer Assembly on Particle Supports: PEtOxMAx and PMA were directly dissolved in 
NaOAc (20 mM, pH 4) to a concentration of 1 g L-1 and pH adjusted. 100 µL silica particles (5 
wt%, 1.16 µm-diameter) were washed three times with 0.5 mL NaOAc (20 mM, pH 4) by 
centrifugation. To form the multilayers, 200 µL of PEtOxMAx (1 g L
-1 in 20 mM NaOAc, pH 4) 
was added to the particle suspension for adsorption (15 min) with constant shaking. The particles 
were then washed via three centrifugation (1000 g, 1 min)/redispersion (300 μL) cycles. As 
second layer, 200 µL of PMA (1 g L-1 in 20 mM NaOAc, pH 4) was added to the particle 
suspension for adsorption (10 min) with constant shaking. The particles were then washed via 
three centrifugation (1000 g, 1 min)/redispersion (300 μL) cycles. This adsorption process was 
repeated with a further four bilayers of PEtOxMAx and PMA (1 g L
-1 in 20 mM NaOAc, pH 4), 
followed by one protective capping bilayer of PVPON and PMA (1 g L-1 in 20 mM NaOAc, pH 
4). 
To follow the assembly of multilayers on particle supports fluorescently labeled PMA (PMA488) 
was used for the buildup to monitor the sequential assembly with flow cytometry. PEtOxMAx 
and PMA488 were alternately adsorbed onto 100 µL silica particles (5 wt%, 1.16 µm-diameter), 
as described above, until 5 bilayers were deposited (i.e., PMA as the terminating layer) onto the 
particle supports. After each adsorption step, the core-shell particles were re-suspended in 20 μL 
NaOAc (20 mM, pH 4) and a 3 µL sample of the particles was taken and analyzed using the flow 
cytometer. 
Crosslinking of the Multilayers: After completion of the assembly and extensive washing, the 
core–shell particles were re-dispersed in 0.5 mL NaOAc (20 mM, pH 4) and incubated in 600 µL 
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bisazide linker (1 g L-1) in the presence of 200 µL sodium ascorbate (4.4 g L-1) and 200 µL 
copper sulfate (1.75 g L-1) (all in 20 mM NaOAc, pH 4) overnight. After washing, the 
crosslinked core–shell particles were re-dispersed in 200 μL of NaOAc (20 mM, pH 4). To this 
suspension, 200 μL of ammonium fluoride (8 M) and 100 μL of hydrofluoric acid (2 M) were 
added for core dissolution, followed by three centrifugation (3200 g, 5 min)/re-dispersion (200 
μL) cycles. Caution! Hydrofluoric acid and ammonium fluoride are very toxic. Extreme care 
should be taken when handling HF solution, and only small quantities should be prepared.   
Labeling of the Capsules: The crosslinked capsules were re-suspended in 200 μL of NaOAc (20 
mM, pH 4) and incubated with a mixture of 3 µL AF488Az (1 g L
-1), 100 µL sodium ascorbate 
(4.4 g L-1), and copper sulfate (1.75 g L-1) (all in 20 mM NaOAc, pH 4). After 5 h of constant 
shaking, the labeled capsules were washed extensively in NaOAc buffer to remove unreacted dye 
and subsequently in PBS (pH 7.4) to remove the sacrificial/capping PVPON and PMA. 
 
Glycopolymer film-ConA interaction studies 
Planar supports: PEtOxMAAlk and PEtOxMAMan films (4 bilayers) were assembled using QCM 
as described above. Crosslinking of the multilayered films was performed by incubation for 24 h 
with nondegradable bisazide linker (1 g L-1), sodium ascorbate (4.4 g L-1), and copper(II) sulfate 
(1.75 g L-1). Subsequently, the films were washed into PBS (pH 7.4) to remove sacrificial PMA 
and prior to the ConA studies into HBS (pH 7.4). The films were incubated in ConA (0.2 mg 
mL-1, HBS) for 3 h and washed into HBS (pH 7.4) to remove unbound ConA.  
Particle supports:  PEtOxMAAlk and PEtOxMAMan capsules (AF488 labeled) were incubated 
with ConA (AF647 labeled) for 3 h under constant shaking. After washing cycles with HBS (pH 
7.4) the capsules were investigated by fluorescence microscopy.  
 
Generation of bone marrow derived DC, MAC and MDSC cultures in vitro 
Bone marrow cells from femurs and tibias of C57BL/6 mice (n=2) were collected and treated 
with ACK lysis buffer (155 mM NHCl4, 10 mM Na-EDTA, 100 mM KHCO3 pH 7.2) for 3-5 
minutes at room temperature to lyse erythrocytes. Cells were pooled, washed and cultured at 5 x 
105 cells/ml in a 24-well plate (1 ml/well) with complete media [RPMI 1640, 2 mM L-glutamine 
(Sigma–Aldrich, Louis, MO, USA), 20 mM HEPES (Sigma–Aldrich, Louis, MO, USA), 0.1 mM 
2-mercaptoethanol (2-ME) (Sigma–Aldrich, Louis, MO, USA), 100 U/ml Penicillin, 100µg/ml 
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of Streptomycin (Sigma–Aldrich, Louis, MO, USA) and 10% of heat-inactivated Foetal Calf 
Serum (FCS) (Sigma–Aldrich, Louis, MO, USA))] at 37oC, 6% CO2. Granulocyte Macrophage-
Colony Stimulating Factor (GM-CSF; PeproTech, Rocky Hill, NJ, USA) (10 ng/ml) was added 
to induce DC generation for 5 days (with a change of culture media at day 3). At day 5, 
PEtOxMAAlk and PEtOxMAMan capsules were added to cells at the final concentration of 30 or 
300 capsules/cell, each condition was tested in quadruplicates. Matching quantities of 
mannosylated polymers on the capsules were also test as controls. The lipopolysaccharide (LPS) 
was used as positive control in the assay. After 18 h co-culture with capsules or control agents, 
cells were harvested and stained with antibodies as shown below. 
 
Flow cytometric analysis 
Cultured cells were harvested and labelled with anti-CD11c V450 (HL3) (BD Biosciences, 
Franklin Lakes, NJ, USA) to identify DC. To study the activation marker expression, cells were 
labelled with anti-CD80 BV650 (BD Biosciences, Franklin Lakes, NJ, USA) and anti-MHCII 
APC-Cy7 (M5/114.15.2) (BD Biosciences, Franklin Lakes, NJ, USA). Dead cell exclusion was 
by LIVE/DEAD Fixable Aqua Dead Cell Stain Kit (Invitrogen, Life Technologies Australia Pty 
Ltd, Victoria Australia). Antibodies were prepared in flow cytometry staining buffer (PBS, 2% 
FCS) and cells were stained for 20 min on ice. Samples were acquired with LSRII (BD 
Biosciences, Franklin Lakes, NJ, USA) at AMREP Flow-Cytometry Core Facility (Melbourne, 
Australia). Data was analyzed with FlowJo Flow Cytometry Analysis Software (TreeStar). 
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